1641 EXTENDED REPORT

First Page		Document Content
Respiratory therapy Autoimmune diseases Connective tissue diseases Mucinoses Respiratory physiology Scleroderma Systemic scleroderma Interstitial lung disease Spirometry Pulmonology Anatomy Medicine		1641 EXTENDED REPORT Add to Reading List Source URL: www.ncbi.nlm.nih.gov Download Document from Source Website File Size: 248,37 KB Share Document on Facebook

	PRESS RELEASE Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading de DocID: 1qCta - View Document
	Technology Opportunity, Ref. No. UZNovel Pharmacological Treatment of Scleroderma This invention relates to a novel pharmacological treatment of scleroderma comprising the administration of miR-29. DocID: 1pOlw - View Document
	Curriculum Vitae BIOGRAPHICAL Name: Janet L. Poole Birthplace: La Jolla, CA Citizenship: USA Business Address: DocID: 1prfA - View Document
	Soluble CD90 as biomarker of pulmonary complications in Systemic Sclerosis A new serological two-staged biomarker of pulmonaryarterial hypertension and pulmonary fibrosis Subtitle Technology DocID: 19Tlu - View Document
	ARTHRITIS INFORMATION SHEET Scleroderma This sheet has been written for people aﬀected by scleroderma. It provides general DocID: 14f19 - View Document